QuidelOrtho Corp (QDEL) FinancialsQDELQuidelOrtho Corp

QuidelOrtho Corp (QDEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Labs, accounting for 60.7% of total sales, equivalent to $382.90M. Other significant revenue streams include Immunohematology and Point-of-Care. Understanding this composition is critical for investors evaluating how QDEL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, QuidelOrtho Corp maintains a gross margin of 35.49%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.03%, while the net margin is -14.72%. These profitability ratios, combined with a Return on Equity (ROE) of -45.91%, provide a clear picture of how effectively QDEL converts its operational activities into shareholder value.

In the context of the broader market, QDEL competes directly with industry leaders such as CSTL and NNNN. With a market capitalization of $980.63M, it holds a significant position in the sector. When comparing efficiency, QDEL's gross margin of 35.49% stands against CSTL's 74.94% and NNNN's 87.24%. Such benchmarking helps identify whether QuidelOrtho Corp is trading at a premium or discount relative to its financial performance.

QuidelOrtho's total revenue has shown fluctuations, with a recent revenue of $630.9 million in Q2 2026, but it has consistently reported net losses, including a net income of -$92.9 million in the same quarter. The gross margin is currently at 35.49%, indicating some profitability but still below optimal levels.